Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
As we step into 2026, explore the resources that captivated our community in 2025, and more importantly, why they mattered.
This real-world study assessed the effectiveness of bebtelovimab (BEB) versus nirmatrelvir/ritonavir (NR) among outpatients with COVID-19 during the Omicron variant era.
In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence has the potential to improve regulatory submissions, underscoring the urgency for sponsors to integrate RWE more strategically into their regulatory playbooks.
As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November.
Chimeric antigen receptor (CAR) T-cell therapy is among the most promising breakthroughs in modern oncology. By genetically engineering a patient’s T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has redefined what is possible in adoptive cellular immunotherapy.
To succeed, biotechs are rethinking how clinical research gets done. RWD, AI, and patient-centric strategies are no longer experimental; they’re emerging as the core toolkit for companies determined to accelerate progress while controlling risk.
The recent ISPOR Europe 2025 conference, held under the inspiring theme ‘Powering Value and Access Through Patient-Centered Collaboration
Real-world data (RWD) plays a crucial role in clinical research and decision-making, yet navigating its complexity remains a significant challenge. RWD typically comes from claims—open or closed—or from electronic health records (EHRs).
I recently had the opportunity to sit down with Danny Levine for an episode of his RARECast podcast to discuss something I’m deeply passionate about: how real-world data (RWD) is transforming the landscape of rare disease research.
At the recent SCOPE Europe conference, I spoke about a fundamental shift redefining the future of clinical research.
When we think about the future of clinical research, it’s easy to picture gleaming technology, seamless data flows, and a world where trials are faster, smarter, and more inclusive. But let’s be honest. We’re not there yet.
We’re proud to announce that our TriNetX LIVE™ platform was recognized as a Best of Show Finalist at the SCOPE Europe conference.
Upcoming Webinar
From Data to Evidence: A Framework for RWD Study Design & Causal Inference
Thursday, July 16 | 11am ET
Generating credible evidence from real-world data (RWD) requires more than access to data — it demands intentional alignment between the research question, study design, and data source. Yet even experienced teams fall into the trap of starting with the data and working backward, a shortcut that can undermine the trustworthiness of study findings.
Join TriNetX Chief Scientific Officer Jeffrey Brown, PhD, and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab at Harvard, as they walk through a practical framework for designing rigorous RWD studies for causal inference. Attendees will leave with concrete tools for sequencing their research approach, evaluating data fitness, and applying sound decision-making to their own studies.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
